AstraZeneca & Daiichi Sankyo: Datroway Approved for Metastatic TNBC FDA approved Datroway today. It targets metastatic TNBC. This is a TROP2-directed ADC. New option for difficult cancer. AstraZeneca and Daiichi Sankyo secured FDA approval for Datroway (datopotamab deruxtecan). This TROP2-directed antibody-drug conjugate (ADC) is now indicated for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC). The approval follows compelling Phase III TROPION-Breast02 trial data, demonstrating significant progression-free survival benefits over chemotherapy in this challenging patient population. The FDA's decision underscores the agency's commitment to accelerating therapies for unmet medical needs, aligning with 21 CFR Part 314 Subpart H (Accelerated Approval). This approval was based on a robust clinical package. The EMA is currently reviewing Datroway for a similar indication, with a decision anticipated by Q4 2026. This parallel regulatory progress highlights the drug's global potential. This approval strengthens AstraZeneca and Daiichi Sankyo's oncology pipeline, particularly in the competitive ADC landscape. It positions Datroway against existing TNBC treatments and emerging ADCs like Trodelvy (sacituzumab govitecan). This provides a crucial new option for patients and solidifies the companies' leadership in targeted cancer therapies.